MK-3577

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H30ClFN2O3
Molecular Weight	521.022
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC[C@@H]([C@@H](C1=CNC2=C(F)C=C(C)C=C12)C3=CC=C(Cl)C=C3)C4=CC=C(C=C4)C(=O)NCCC(O)=O

InChI

InChIKey=FYRJJCYFYLLOSC-LXFBAYGMSA-N

InChI=1S/C30H30ClFN2O3/c1-3-4-23(19-5-7-21(8-6-19)30(37)33-14-13-27(35)36)28(20-9-11-22(31)12-10-20)25-17-34-29-24(25)15-18(2)16-26(29)32/h5-12,15-17,23,28,34H,3-4,13-14H2,1-2H3,(H,33,37)(H,35,36)/t23-,28+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C30H30ClFN2O3
Molecular Weight	521.022
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:42:29 UTC 2023` Edited by `admin` on `Sat Dec 16 11:42:29 UTC 2023`
Record UNII	03TW1410NL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MK-3577

Common Name

English

.BETA.-ALANINE, N-(4-((1S)-1-((R)-(4-CHLOROPHENYL)(7-FLUORO-5-METHYL-1H-INDOL-3-YL)METHYL)BUTYL)BENZOYL)-

Systematic Name

English

N-(4-((1S)-1-((R)-(4-CHLOROPHENYL)(7-FLUORO-5-METHYL-1H-INDOL-3-YL)METHYL)BUTYL)BENZOYL)-.BETA.-ALANINE

Systematic Name

English

N-(4-((1S)-1-((R)-(4-CHLOROPHENYL)(7-FLUORO-5-METHYL-1H-INDOL-3-YL)METHYL)BUTYL)BENZOYL)-.BETA.-ALANINE, (-)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

46240797

Created by admin on Sat Dec 16 11:42:29 UTC 2023 , Edited by admin on Sat Dec 16 11:42:29 UTC 2023

PRIMARY

DRUG BANK

DB14957

Created by admin on Sat Dec 16 11:42:29 UTC 2023 , Edited by admin on Sat Dec 16 11:42:29 UTC 2023

PRIMARY

FDA UNII

03TW1410NL

Created by admin on Sat Dec 16 11:42:29 UTC 2023 , Edited by admin on Sat Dec 16 11:42:29 UTC 2023

PRIMARY

CAS

1019112-29-8

Created by admin on Sat Dec 16 11:42:29 UTC 2023 , Edited by admin on Sat Dec 16 11:42:29 UTC 2023

PRIMARY

Related Record Type Details


					G2BWF9H576

GLUCAGON RECEPTOR

TARGET -> INHIBITOR

Comments:

More complete GCGr blockade led to better glycemic control, but also LDL-C increases, whereas partial GCGr blockade led to smaller effects on glycemic control and LDL-C.

Related Record Type Details


					03TW1410NL

MK-3577

ACTIVE MOIETY

Comments:

Purpose: This study will assess the safety and efficacy of MK3577 when given in the morning, the evening, or twice a day as compared to placebo and to metformin.


					03TW1410NL

MK-3577

ACTIVE MOIETY

Comments:

Originator: Merck & Co; Class: Anti-hyper-glycaemic; Mechanism of Action: Glucagon receptor antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Discontinued for Type 2 diabetes mellitus; Most Recent Event: 08 Mar 2010 MK 3577 is still in phase II development